Trials / Unknown
UnknownNCT03423706
Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- First Affiliated Hospital of Harbin Medical University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Building a new haploid transplanted model with high-dose CTX、CD19-CART,donor CD34+ hematopoietic stem cell and Tregs,to prevent graft-versus-host disease(GVHD),reduce the infection,promote the rate of immune reconstruction，seperate graft versus leukemia（GVL）and GVHD，then to reduce the relapse rate after hematopoietic stem cell transplantation（HSCT）for relapsed and/or refractory B cell acute lymphoblastic leukemia（r/r-B-ALL）.
Detailed description
compare the new haplo-HSCT model with the traditional haplo-HSCT in DFS、OS、RFS、CR and the degree of GVHD.etc.for the r/r B-ALL patients.
Conditions
- CD19-chimeric Antigen Receptor T Cells
- Relapsed and/or Refractory Acute Lymphoblastic Leukemia
- the Haploidentical Hematopoietic Stem Cell Transplantation
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | the new model of haplo-HSCT for r/r B-ALL | take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT. |
Timeline
- Start date
- 2018-05-07
- Primary completion
- 2020-12-01
- Completion
- 2021-12-01
- First posted
- 2018-02-06
- Last updated
- 2019-12-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03423706. Inclusion in this directory is not an endorsement.